Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19-CAR CMV-specific T lymphocytes

A preparation of human cytomegalovirus (CMV)-specific T lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-CAR CMV-specific T lymphocytes recognize, bind to, and induce selective toxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. The anti-CD19-CAR CMV-specific T lymphocytes may potentially be expanded in vivo through CMV vaccination.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD19-CAR CMV-specific T cells
CMV-specific CD19 CAR T Cells
CMV-specific CD19-CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search